Fc engineered anti‐virus therapeutic human IgG 1 expressed in plants with altered binding to the neonatal Fc receptor
Biotechnology Journal · 2024
DOI: 10.1002/biot.202300552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2024. Verfasst von Sol-Ah Park und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, BioSystems Design Lab, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Histocompatibility Antigens Class I, Immunoglobulin G, Receptors, Fc. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Korean government (MSIT), Mid-career Researcher Program, Medical Research Center (MRC).
Abstract (Originalsprache)
Production of therapeutic monoclonal antibody (mAb) in transgenic plants has several advantages such as large‐scale production and the absence of pathogenic animal contaminants. However, mAb with high mannose (HM) type glycans has shown a faster clearance compared to antibodies produced in animal cells. The neonatal Fc receptor (FcRn) regulates the persistence of immunoglobulin G (IgG) by the FcRn‐mediated recycling pathway, which salvages IgG from lysosomal degradation within cells. In this study, Fc‐engineering of antirabies virus therapeutic mAb SO57 with the endoplasmic reticulum (ER)‐retention peptide signal (Lys‐Asp‐Glu‐Leu; KDEL) (mAb p K SO57) in plant cell was conducted to enhance its binding activity to human neonatal Fc receptor (hFcRn), consequently improve its serum half‐life. Enzyme‐linked immunosorbent assay (ELISA) and Surface plasmon resonance assay showed altered binding affinity of the Fc region of three different mAb p K SO57 variants [M252Y/S254T/T256E (MST), M428L/N434S (MN), H433K/N434F (HN)] to hFcRn compared to wild type (WT) of mAb p K SO57. Molecular modeling data visualized the structural alterations in these mAb p K SO57. All of the mAb p K SO57 variants had HM type glycan structures similar to the WT mAb p K SO57. In addition, the neutralizing activity of the three variants against the rabies virus CVS‐11 was effective as the WT mAb p K SO57. These results indicate that the binding affinity of mAb p K SO57 variants to hFcRn can be modified without alteration of N‐ glycan structure and neutralization activity. Taken together, this study suggests that Fc‐engineering of antirabies virus mAb can be applied to enhance the efficacy of therapeutic mAbs in plant expression systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, BioSystems Design Lab, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea.
- College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
- Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon, Republic of Korea.
- Department of Applied Experimental Biophysics, Johannes Kepler University Linz, Linz, Austria.
- Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
ORCID-Profile: Kisung Ko
Förderung
- Korean government (MSIT)
- Mid-career Researcher Program
- Medical Research Center (MRC)
- Bio & Medical Technology Development Program
- Young Researcher Program
Zitieren
APA
Park, S. A., Lee, Y., Hwang, H., Lee, J. H., Kang, Y. J., Kim, Y., Jin, C., An, H. J., Oh, Y. J., Hinterdorfer, P., Kim, E., Choi, S., & Ko, K. (2024). Fc engineered anti‐virus therapeutic human IgG 1 expressed in plants with altered binding to the neonatal Fc receptor. Biotechnology Journal. https://doi.org/10.1002/biot.202300552
Vancouver
Park SA, Lee Y, Hwang H, Lee JH, Kang YJ, Kim Y, et al. Fc engineered anti‐virus therapeutic human IgG 1 expressed in plants with altered binding to the neonatal Fc receptor. Biotechnology Journal. 2024. doi:10.1002/biot.202300552
BibTeX
@article{Park2024,
author = {Park, Sol-Ah and Lee, Yoonji and Hwang, Hyunjoo and Lee, Jeong Hwan and Kang, Yang Joo and Kim, Yerin and Jin, Caiquan and An, Hyun Joo and Oh, Yoo Jin and Hinterdorfer, Peter and Kim, Eunhye and Choi, Sun and Ko, Kisung},
title = {Fc engineered anti‐virus therapeutic human IgG 1 expressed in plants with altered binding to the neonatal Fc receptor},
journal = {Biotechnology Journal},
year = {2024},
doi = {10.1002/biot.202300552}
}
EUVIMED